SH3BP2 mutations potentiate osteoclastogenesis via PLCγ

Journal of Orthopaedic Research

Volumn 28, Issue 11, 2010, Pages 1425-1430

  Lietman, Steven A ^a   Yin, Lihong ^a   Levine, Michael A ^a,b  

^a LERNER RESEARCH INSTITUTE   (United States)

^b UNIVERSITY OF PENNSYLVANIA   (United States)

Author keywords

Bone and cartilage development; Bone turnover; Osteoclasts; Osteoporosis

Indexed keywords

OSTEOCLAST DIFFERENTIATION FACTOR; PHOSPHOLIPASE C GAMMA; SH3BP2 PROTEIN, MOUSE; SIGNAL TRANSDUCING ADAPTOR PROTEIN; TRANSCRIPTION FACTOR NFAT;

ANIMAL; ARTICLE; CELL CULTURE; GENETICS; METABOLISM; MOUSE; MUTATION; OSTEOCLAST; PHYSIOLOGY;

ADAPTOR PROTEINS, SIGNAL TRANSDUCING; ANIMALS; CELLS, CULTURED; MICE; MUTATION; NFATC TRANSCRIPTION FACTORS; OSTEOCLASTS; PHOSPHOLIPASE C GAMMA; RANK LIGAND;

EID: 77957945598     PISSN: 07360266     EISSN: 1554527X     Source Type: Journal    
DOI: 10.1002/jor.21164     Document Type: Article

References (35)

1. Takayanagi H. 2005. Mechanistic insight into osteoclast differentiation in osteoimmunology. J Mol Med 83:170-179.
2. Faccio R, Teitelbaum SL, Fujikawa K, et al. 2005. Vav3 regulates osteoclast function and bone mass. Nat Med 11:284-290.
3. Mao D, Epple H, Uthgenannt B, et al. 2006. PLCgamma2 regulates osteoclastogenesis via its interaction with ITAM proteins and GAB2. J Clin Invest 116:2869-2879.
4. Ueki Y, Lin CY, Senoo M, et al. 2007. Increased myeloid cell responses to M-CSF and RANKL cause bone loss and inflammation in SH3BP2 "cherubism" mice. Cell 128:71-83.
5. Shinohara M, Koga T, Okamoto K, et al. 2008. Tyrosine kinases Btk and Tec regulate osteoclast differentiation by linking RANK and ITAM signals. Cell 132:794-806.
6. Takayanagi H, Kim S, Koga T, et al. 2002. Induction and activation of the transcription factor NFATc1 (NFAT2) integrate RANKL signaling in terminal differentiation of osteoclasts. Dev Cell 3:889-901.
7. Lietman SA, Yin L, Levine MA. 2008. SH3BP2 is an activator of NFAT activity and osteoclastogenesis. Biochem Biophys Res Commun 371:644-648.
8. Ueki Y, Tiziani V, Santanna C, et al. 2001. Mutations in the gene encoding c-Abl-binding protein SH3BP2 cause cherubism. Nat Genet 28:125-126.
9. Schultze-Mosgau S, Holbach LM, Wiltfang J. 2003. Cherubism: Clinical evidence and therapy. J Craniofac Surg 14:201-206, discussion 207-208.
10. Pulse CL, Moses MS, Greenman D, et al. 2001. Cherubism: Case reports and literature review. Dent Today 20:100-103.
11. Petschler M, Stiller M, Hoffmeister B, et al. 2003. Clinical and molecular genetic observations on families with cherubism over three generations. Mund Kiefer Gesichtschir 7:83-87.
12. Lannon DA, Earley MJ. 2001. Cherubism and its charlatans. Br J Plast Surg 54:708-711.
13. Ladhani S, Sundaram P, Joshi JM. 2003. Sleep disordered breathing in an adult with cherubism. Thorax 58:552.
14. Lo B, Faiyaz-Ul-Haque M, Kennedy S, et al. 2003. Novel mutation in the gene encoding c-Abl-binding protein SH3BP2 causes cherubism. Am J Med Genet 121A:37-340.
15. Ren R, Mayer BJ, Cicchetti P, et al. 1993. Identification of a ten-amino acid proline-rich SH3 binding site. Science 259:1157-1161.
16. Lietman SA, Kalinchinko N, Deng X, et al. 2006. Identification of a novel mutation of SH3BP2 in cherubism and demonstration that SH3BP2 mutations lead to increased NFAT activation. Hum Mutat 27:717-718.
17. Imai Y, Kanno K, Moriya T, et al. 2003. Amissense mutation in the SH3BP2 gene on chromosome 4p16.3 found in a case of nonfamilial cherubism. Cleft Palate Craniofac J 40:632-638.
18. Carvalho VM, Perdigao PF, Pimenta FJ, et al. 2007. A novel mutation of the SH3BP2 gene in an aggressive case of cherubism. Oral Oncol 44:153-155.
19. de Lange J, van Maarle MC, van den Akker HP, et al. 2007. A new mutation in the SH3BP2 gene showing reduced penetrance in a family affected with cherubism. Oral Surg Oral Med Oral Pathol Oral Radiol Endod 103:378-381.
20. Li CY, Yu SF. 2006. A novel mutation in the SH3BP2 gene causes cherubism: Case report. BMC Med Genet 7:84.
21. Bergemann AD, Cole F, Hirschhorn K. 2005. The etiology of Wolf-Hirschhorn syndrome. Trends Genet 21:188-195.
22. Battaglia A, Carey JC. 1999. Health supervision and anticipatory guidance of individuals with Wolf-Hirschhorn syndrome. Am J Med Genet 89:111-115.
23. Battaglia A, Carey JC, Cederholm P, et al. 1999. Natural history of Wolf-Hirschhorn syndrome: Experience with 15 cases. Pediatrics 103:830-836.
24. Deckert M, Tartare-Deckert S, Hernandez J, et al. 1998. Adaptor function for the Syk kinases-interacting protein 3BP2 in IL-2 gene activation. Immunity 9:595-605.
25. Foucault I, Liu YC, Bernard A, et al. 2003. The chaperone protein 14-3-3 interacts with 3BP2/SH3BP2 and regulates its adapter function. J Biol Chem 278:7146-7153.
26. Foucault I, Le Bras S, Charvet C, et al. 2005. The adaptor protein 3BP2 associates with VAV guanine nucleotide exchange factors to regulate NFAT activation by the B-cell antigen receptor. Blood 105:1106-1113.
27. Hirotani H, Tuohy NA, Woo JT, et al. 2004. The calcineurin/ nuclear factor of activated T cells signaling pathway regulates osteoclastogenesis in RAW264.7 cells. J Biol Chem 279:13984-13992.
28. Ishida N, Hayashi K, Hoshijima M, et al. 2002. Large scale gene expression analysis of osteoclastogenesis in vitro and elucidation of NFAT2 as a key regulator. J Biol Chem 277:41147-41156.
29. Patterson RL, van Rossum DB, Ford DL, et al. 2002. Phospholipase C-gamma is required for agonist-induced Ca2+entry. Cell 111:529-541.
30. Wilde JI, Watson SP. 2001. Regulation of phospholipase C gamma isoforms in haematopoietic cells: Why one, not the other? Cell Signal 13:691-701.
31. Rebecchi MJ, Pentyala SN. 2000. Structure, function, and control of phosphoinositide-specific phospholipase C. Physiol Rev 80:1291-1335.
32. Katan M. 1998. Families of phosphoinositide-specific phospholipase C: Structure and function. Biochim Biophys Acta 1436:5-17.
33. Hur EM, Park YS, Lee BD, et al. 2004. Sensitization of epidermal growth factor-induced signaling by bradykinin is mediated by c-Src. Implications for a role of lipid microdomains. J Biol Chem 279:5852-5860.
34. Jongstra-Bilen J, Puig Cano A, Hasija M, et al. 2008. Dual functions of Bruton's tyrosine kinase and Tec kinase during Fcgamma receptor-induced signaling and phagocytosis. J Immunol 181:288-298.
35. Aliprantis AO, Ueki Y, Sulyanto R, et al. 2008. NFATc1 in mice represses osteoprotegerin during osteoclastogenesis and dissociates systemic osteopenia from inflammation in cherubism. J Clin Invest 118:3775-3789.